Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
Meghan E SiseDavid S GoldbergJens J KortDouglas E SchaubelRita R AllowayChristine M DurandRobert J FontanaRobert S BrownJohn J FriedewaldStacey PrennerJ Richard LandisMelissa FernandoCaitlin C PhillipsE Steve WoodleAdele Rike-ShieldsKenneth E ShermanNahel EliasWinfred W WilliamsJenna L GustafsonNiraj M DesaiBrittany BarnabaSilas P NormanMona DoshiSamuel T SultanMeredith J AullJosh LevitskyDianne S BelsheRaymond T ChungPeter Philip ReesePublished in: Journal of the American Society of Nephrology : JASN (2020)
Our multicenter trial demonstrated safety and efficacy of transplantation of 30 HCV-viremic kidneys into HCV-negative recipients, followed by early initiation of an 8-week regimen of glecaprevir and pibrentasvir.